• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

成人糖尿病肾病患者血脂管理临床实践指南：英国临床糖尿病学家协会和英国肾脏病协会联合指南（ABCD-UKKA）2024 年版概要

Clinical practice guideline for the management of lipids in adults with diabetic kidney disease: abbreviated summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2024.

机构信息

East and North Herts NHS Trust, Hertfordshire, UK.

University of Glasgow, Glasgow, UK.

出版信息

BMC Nephrol. 2024 Jul 6;25(1):216. doi: 10.1186/s12882-024-03664-1.

DOI:10.1186/s12882-024-03664-1
PMID:38971750
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11227212/
Abstract

The contribution of chronic kidney disease (CKD) towards the risk of developing cardiovascular disease (CVD) is magnified with co-existing type 1 or type 2 diabetes. Lipids are a modifiable risk factor and good lipid management offers improved outcomes for people with diabetic kidney disease (DKD).The primary purpose of this guideline, written by the Association of British Clinical Diabetologists (ABCD) and UK Kidney Association (UKKA) working group, is to provide practical recommendations on lipid management for members of the multidisciplinary team involved in the care of adults with DKD.

摘要

慢性肾脏病（CKD）合并 1 型或 2 型糖尿病会显著增加心血管疾病（CVD）的发病风险。血脂是一个可改变的危险因素，良好的血脂管理可以改善糖尿病肾病（DKD）患者的预后。本指南由英国临床糖尿病学家协会（ABCD）和英国肾脏病协会（UKKA）工作组撰写，主要目的是为多学科团队成员提供有关 DKD 成人血脂管理的实用建议。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3315/11227212/0948e6483dd7/12882_2024_3664_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3315/11227212/0948e6483dd7/12882_2024_3664_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3315/11227212/0948e6483dd7/12882_2024_3664_Fig1_HTML.jpg

相似文献

1
Clinical practice guideline for the management of lipids in adults with diabetic kidney disease: abbreviated summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2024.成人糖尿病肾病患者血脂管理临床实践指南：英国临床糖尿病学家协会和英国肾脏病协会联合指南（ABCD-UKKA）2024 年版概要
BMC Nephrol. 2024 Jul 6;25(1):216. doi: 10.1186/s12882-024-03664-1.
2
Current management of chronic kidney disease in type-2 diabetes-A tiered approach: An overview of the joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) guidelines.2型糖尿病慢性肾脏病的当前管理——分层方法：英国临床糖尿病学家协会和英国肾脏协会联合指南概述
Diabet Med. 2025 Feb;42(2):e15450. doi: 10.1111/dme.15450. Epub 2024 Oct 17.
3
Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease.成人糖尿病肾病高血糖管理的临床实践指南
Diabet Med. 2022 Apr;39(4):e14769. doi: 10.1111/dme.14769. Epub 2022 Jan 26.
4
Management of Hypertension in Patients With Diabetic Kidney Disease: Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021.糖尿病肾病患者的高血压管理：英国临床糖尿病学家协会和英国肾脏协会联合指南（ABCD-UKKA）2021年总结
Kidney Int Rep. 2022 Jan 13;7(4):681-687. doi: 10.1016/j.ekir.2022.01.004. eCollection 2022 Apr.
5
Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021.成人糖尿病肾脏疾病患者的高血压和肾素-血管紧张素-醛固酮系统阻滞剂管理：英国临床糖尿病学家协会和英国肾脏协会 2021 年指南更新。
BMC Nephrol. 2022 Jan 3;23(1):9. doi: 10.1186/s12882-021-02587-5.
6
Managing diabetic kidney disease.管理糖尿病肾病。
Br Med Bull. 2018 Mar 1;125(1):55-66. doi: 10.1093/bmb/ldx047.
7
Impact of chronic kidney disease definition on assessment of its incidence and risk factors in patients with newly diagnosed type 1 and type 2 diabetes in the UK: A cohort study using primary care data from the United Kingdom.英国一项基于初级保健数据的队列研究：慢性肾脏病定义对新诊断 1 型和 2 型糖尿病患者发病和风险因素评估的影响。
Prim Care Diabetes. 2020 Aug;14(4):381-387. doi: 10.1016/j.pcd.2019.11.002. Epub 2019 Nov 30.
8
Diabetic kidney disease: a report from an ADA Consensus Conference.糖尿病肾病：ADA 共识会议报告。
Am J Kidney Dis. 2014 Oct;64(4):510-33. doi: 10.1053/j.ajkd.2014.08.001.
9
Multidisciplinary management of diabetic kidney disease: a systematic review and meta-analysis.糖尿病肾病的多学科管理：一项系统评价与荟萃分析
JBI Database System Rev Implement Rep. 2016 Jul;14(7):169-207. doi: 10.11124/JBISRIR-2016-003011.
10
Inequalities in the management of diabetic kidney disease in UK primary care: A cross-sectional analysis of a large primary care database.英国初级医疗中糖尿病肾病管理的不平等：对一个大型初级医疗数据库的横断面分析
Diabet Med. 2024 Jan;41(1):e15153. doi: 10.1111/dme.15153. Epub 2023 Jun 14.

引用本文的文献

1
Chitosan-Based Nanoparticles Targeted Delivery System: In Treatment Approach for Dyslipidemia.基于壳聚糖的纳米颗粒靶向递送系统：在血脂异常治疗方法中的应用
Int J Nanomedicine. 2025 May 24;20:6611-6636. doi: 10.2147/IJN.S517492. eCollection 2025.
2
Comprehensive Review of Lipid Management in Chronic Kidney Disease and Hemodialysis Patients: Conventional Approaches, and Challenges for Cardiovascular Risk Reduction.慢性肾脏病和血液透析患者血脂管理的全面综述：传统方法及降低心血管风险面临的挑战
J Clin Med. 2025 Jan 20;14(2):643. doi: 10.3390/jcm14020643.
3
A New Era in Diabetic Kidney Disease Treatment: The Four Pillars and Strategies to Build Beyond.

本文引用的文献

1
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.贝匹地酸在他汀类药物不耐受患者中的心血管结局。
N Engl J Med. 2023 Apr 13;388(15):1353-1364. doi: 10.1056/NEJMoa2215024. Epub 2023 Mar 4.
2
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials.依洛西仑和心血管事件：III 期临床试验的患者水平分析。
Eur Heart J. 2023 Jan 7;44(2):129-138. doi: 10.1093/eurheartj/ehac594.
3
Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease.成人糖尿病肾病高血糖管理的临床实践指南
糖尿病肾病治疗的新时代：四大支柱及未来发展策略
Electrolyte Blood Press. 2024 Dec;22(2):21-28. doi: 10.5049/EBP.2024.22.2.21. Epub 2024 Dec 30.
4
Current management of chronic kidney disease in type-2 diabetes-A tiered approach: An overview of the joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) guidelines.2型糖尿病慢性肾脏病的当前管理——分层方法：英国临床糖尿病学家协会和英国肾脏协会联合指南概述
Diabet Med. 2025 Feb;42(2):e15450. doi: 10.1111/dme.15450. Epub 2024 Oct 17.
5
Novel Insights into Diabetic Kidney Disease.糖尿病肾病的新见解。
Int J Mol Sci. 2024 Sep 23;25(18):10222. doi: 10.3390/ijms251810222.
Diabet Med. 2022 Apr;39(4):e14769. doi: 10.1111/dme.14769. Epub 2022 Jan 26.
4
Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021.成人糖尿病肾脏疾病患者的高血压和肾素-血管紧张素-醛固酮系统阻滞剂管理：英国临床糖尿病学家协会和英国肾脏协会 2021 年指南更新。
BMC Nephrol. 2022 Jan 3;23(1):9. doi: 10.1186/s12882-021-02587-5.
5
Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance.CLEAR-outcomes 试验的原理和设计：评估贝匹地酸在他汀类药物不耐受患者中的心血管事件的影响。
Am Heart J. 2021 May;235:104-112. doi: 10.1016/j.ahj.2020.10.060. Epub 2020 Oct 24.
6
Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.高剂量ω-3 脂肪酸与玉米油对高心血管风险患者主要不良心血管事件的影响： STRENGTH 随机临床试验。
JAMA. 2020 Dec 8;324(22):2268-2280. doi: 10.1001/jama.2020.22258.
7
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.英克西兰用于治疗杂合子家族性高胆固醇血症。
N Engl J Med. 2020 Apr 16;382(16):1520-1530. doi: 10.1056/NEJMoa1913805. Epub 2020 Mar 18.
8
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.两项降低 LDL 胆固醇的依洛尤单抗 3 期临床试验。
N Engl J Med. 2020 Apr 16;382(16):1507-1519. doi: 10.1056/NEJMoa1912387. Epub 2020 Mar 18.
9
Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.贝匹地酸对比安慰剂联合最大耐受他汀类药物治疗对心血管疾病高危患者的低密度脂蛋白胆固醇的影响：CLEAR Wisdom 随机临床试验。
JAMA. 2019 Nov 12;322(18):1780-1788. doi: 10.1001/jama.2019.16585.
10
Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies.肾功能损害对 Inclisiran 药代动力学、疗效和安全性的影响：ORION-7 和 ORION-1 研究分析。
Mayo Clin Proc. 2020 Jan;95(1):77-89. doi: 10.1016/j.mayocp.2019.08.021. Epub 2019 Oct 17.